SiBone (NASDAQ:SIBN) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

SiBone (NASDAQ:SIBN) posted its quarterly earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.06, FiscalAI reports. The company had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.31% and a negative net margin of 6.85%.

Here are the key takeaways from SiBone’s conference call:

• Second-quarter revenue rose 15.2% to $56 million, with U.S. procedure volume up nearly 15% and growth across SI joint fusion, pelvic fixation, and pelvic trauma. International revenue increased 25.9% to $2.8 million.
• Operating leverage improved substantially as operating expenses grew 7.7%, driving a 178% increase in adjusted EBITDA to $2.8 million and narrowing the net loss to $4.1 million. The company also reported another quarter of positive operating cash flow and ended with approximately $146 million in cash.
• SI-BONE raised the low end of its 2026 worldwide revenue outlook to $231 million-$233 million, while maintaining its 79% gross-margin expectation. Management cited strong physician growth, expanded commercial capacity, and multiple upcoming catalysts.
• The company submitted its third breakthrough-device 510(k) application in June and expects a phased launch as early as October, using existing relationships with spine surgeons. New CMS reimbursement proposals and finalized Granite-related DRGs could materially improve procedure economics, including potential hospital payment increases of up to $50,000 per procedure.
• Management plans to increase targeted R&D spending in the second half to advance new materials, software, AI, and additional products, while investing in surgical capacity and a new headquarters. These investments may create long-term growth but could cause near-term cash-flow variability and pressure margins through additional depreciation.

SiBone Stock Performance

SIBN stock traded down $0.52 during mid-day trading on Wednesday, reaching $17.92. 128,864 shares of the stock traded hands, compared to its average volume of 630,071. The firm has a market capitalization of $794.75 million, a PE ratio of -45.95 and a beta of 0.66. The business has a 50-day moving average of $16.38 and a two-hundred day moving average of $15.13. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SIBN. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. TD Cowen upped their target price on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial reaffirmed a “buy” rating and set a $23.00 price objective (up from $21.00) on shares of SiBone in a research report on Tuesday. UBS Group lifted their target price on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.29.

Insider Buying and Selling

In other news, Director Timothy E. Davis, Jr. sold 3,780 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $14.47, for a total transaction of $54,696.60. Following the transaction, the director owned 69,222 shares in the company, valued at approximately $1,001,642.34. The trade was a 5.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Anshul Maheshwari sold 3,317 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $16.77, for a total value of $55,626.09. Following the transaction, the chief financial officer owned 256,560 shares in the company, valued at $4,302,511.20. This represents a 1.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 35,989 shares of company stock worth $541,229. 4.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On SiBone

A number of institutional investors have recently added to or reduced their stakes in SIBN. Royal Bank of Canada lifted its holdings in SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after purchasing an additional 1,941 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of SiBone in the fourth quarter valued at $53,000. State of Wyoming bought a new position in shares of SiBone in the second quarter valued at about $55,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of SiBone in the second quarter valued at about $68,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.